Table 2

Patient characteristics at start of niraparib treatment

Characteristics(N, %)
Age, years (median, range)64, 38–81
Co-morbidity (Charlson Comorbidity Index*)
 08 (8.5)
 1–252 (55.3)
 ≥334 (36.2)
Previous lines of chemotherapy
 264 (68.1)
 317 (18.1)
 ≥413 (13.8)
Debulking surgery at relapse
 No87 (92.6)
 Yes, preceding last line of chemotherapy4 (4.3)
 Yes, not preceding last line of chemotherapy3 (3.2)
Type of chemotherapy preceding niraparib
 Platinum combination87 (92.6)
 Platinum single6 (6.4)
 Non-platinum1 (1.1)
Previous bevacizumab treatment
 Yes44 (46.8)
 No50 (53.2)
Response of chemotherapy preceding niraparib†
 CR11 (11.7)
 PR73 (77.7)
 SD6 (6.4)
 Non-evaluable‡4 (4.3)
CA125 level
 ≤35 kU/L54 (57.4)
 >35 kU/L40 (42.6)
Start dosage
 200 mg29 (30.9)
 300 mg65 (69.1)
Weight
 <77 kg69 (73.4)
 ≥77 kg25 (26.6)
  • *Age adjusted.

  • †Investigator assessed.

  • ‡No computed tomography scan performed after surgery with no residual tumor.

  • CR, complete response; PR, partial response; SD, stable disease.